Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
NCT05597800
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
105
Enrollment
OTHER
Sponsor class
Conditions
NSCLC Stage IV
HIV
HBV
HCV
Long COVID
Interventions
DRUG:
Nivolumab and Ipilimumab
Sponsor
Universita di Verona